The Special Stockholder Meeting on August 28, 2025 recorded the proxy voting approvals of all ten of the Windtree proposals by stockholders The stockholder approved proposals provide the foundation for Windtree revenue generating deals in environmental services Windtree is choosing to focus on environmental services and other revenue generating businesses – the Company will not move forward with the cryptocurrency treasury strategy Company continues to move forward with potential deals for both biotech asse ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39290 WINDTREE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or o ...

Acute decompensated heart failure and cardiogenic shock have had very little drug innovation in decades. The Company believes istaroxime has a profile that offers potential benefits to patients with low blood pressure due to heart failure. Istaroxime improves cardiac function and can increase blood pressure without increasing heart rate. Also, istaroxime tends to preserve measures of renal function and contributes to resolution of congestion and fluid overload that often accompanies heart failure. Important ...

Istaroxime was added to currently available inotropes and vasopressors in the study - no new safety signals were identified and physiological improvements were consistent with istaroxime responses in previous trials The SEISMiC C Study is a global trial including sites in the U.S., Europe and Latin America. It is placebo- controlled, double-blinded study with istaroxime being added to current standard of care, including inotropes or vasopressors in patients with more severe cardiogenic shock (SCAI stage C) ...

Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build Corp displaying the underlying demand for the coin globally WARRINGTON, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a b ...

Biotech Firm Goes Crypto, Plans $520M BNB PushWindtree Therapeutics is a publicly listed biotech company (WINT) that develops treatments for acute cardiovascular and pulmonary conditions.It is now planning to raise up to $520M through equity agreements to build a BNB reserve, directing 99% of the funds toward acquiring BNB as part of its treasury diversification strategy, with nearly $700M committed in total.Pending shareholder approval to increase authorized shares, Windtree has also partnered with Kraken ...

Funding & Investment - Windtree Therapeutics (WINT), a Nasdaq-listed biotech company, secured up to $520 million in total funding [1] - The funding includes a $500 million equity line of credit (ELOC) agreement and an additional $20 million stock purchase deal [1] - Approximately 99% of the funds, equivalent to roughly $514.8 million, will be allocated to buy BNB (币安币) [1]

Core Viewpoint - Windtree Therapeutics, Inc. has committed up to $700 million for BNB acquisitions, emphasizing its innovative cryptocurrency treasury strategy [1][2]. Group 1: Financial Commitments - The company has entered into a Common Stock Purchase Agreement for up to $500 million to establish an equity line of credit (ELOC) [1]. - An additional $20 million stock purchase agreement has been made with Build and Build Corp [1]. - Ninety-nine percent of the proceeds from both agreements will be allocated to acquiring BNB cryptocurrency [1]. Group 2: Strategic Intent - The establishment of the ELOC is part of Windtree's strategy to diversify its treasury assets and leverage blockchain-based digital currencies [2]. - The CEO of Windtree highlighted the importance of securing additional funds for purchasing BNB as essential to the company's strategy [2]. - The integration of BNB into the treasury is viewed as a forward-thinking approach to value creation [3]. Group 3: Company Background - Windtree Therapeutics is a diversified company with a focus on a cryptocurrency treasury strategy and therapeutic pipelines [4]. - Build and Build Corp is a company with expertise in hedge funds and digital asset management, backed by prominent investors [5].

The Binance Smart Chain (BSC) supports a thriving decentralized finance (DeFi) ecosystem with thousands of decentralized applications (dApps) and millions of users, driven by BNB's high liquidity and average daily trading volumes exceeding $2 billion. This partnership positions Windtree to capitalize on the global growth potential of the Binance ecosystem, particularly in the U.S. market. The Kraken term sheet is subject to shareholder approval of Windtree's previously announced securities purchase agreemen ...

Core Viewpoint - Windtree Therapeutics, Inc. is set to become the first NASDAQ-listed company providing direct exposure to the Binance Smart Chain Ecosystem through a $60 million securities purchase agreement, with potential total subscriptions of up to $200 million [1][4] Group 1: Financial Strategy - The financing will primarily be used to launch a BNB crypto treasury strategy and purchase BNB, positioning Windtree as a leader in the BNB digital asset space [1][2] - The transaction is expected to establish a robust BNB Crypto Treasury Strategy, including custody, security, and yield generation [2] Group 2: Market Positioning - Windtree aims to fill a critical gap in the U.S. investment landscape by offering targeted exposure to Binance and BNB [3] - BNB is recognized as the largest and most liquid crypto exchange token globally, with average daily trading volumes exceeding $2 billion [3] Group 3: Company Background - Windtree Therapeutics operates with several divisions, including a cryptocurrency treasury strategy and therapeutic pipelines [5] - Build and Build Corp, involved in the transaction, has over 43 years of expertise in hedge funds and digital asset management, backed by prominent investors [6]